Zotatifin (eFT226) is a potent eIF4A1 inhibitor. It affects JNK, NRF2, and E2F1 signaling pathways, and by inducing JNK phosphorylation and downregulating NRF2, it inhibits tumor proliferation and metastasis, and promotes apoptosis.
Zotatifin (eFT226) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Zotatifin (eFT226) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.
Jump to
- Zotatifin (eFT226) Mechanism of Action: eIF4A Inhibition in Breast Cancer Cell Research
- Zotatifin (eFT226) Clinical Trials
- Zotatifin (eFT226) Working Concentration | Cell Culture | Treatment
- Zotatifin (eFT226) Solubility in DMSO
- Zotatifin (eFT226) Stock Solution
- Zotatifin (eFT226) Storage
- Zotatifin (eFT226) Stability
- Zotatifin (eFT226) Combination Database
- Zotatifin (eFT226) Molecular Weight
- Zotatifin (eFT226) SMILES
- Zotatifin (eFT226) CAS Number
- Zotatifin (eFT226) Chemical Structure (2D and 3D)
- Zotatifin (eFT226) APExBIO (BA2258)? Try a better option.
- Zotatifin (eFT226) MedChemExpress (HY-112163)? Try a better option.
- Zotatifin (eFT226) Sigma (BL3H9AC9783C)? Try a better option.
- Zotatifin (eFT226) SDS｜MSDS